References
- June CH, Blazar BR, Riley JL. Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol. 2009;9: 704–16.
- Brentjens RJ. Cellular therapies in acute lymphoblastic leukaemia. Curr Opin Mol Ther. 2009;11:375–82.
- Scopelliti A, Cammareri P, Catalano V, Saladino V, Todaro M, Stassi G. Therapeutic implications of cancer initiating cells. Expert Opin Biol Ther. 2009;9:1005–16.
- Garcia-Castro J, Trigueros C, Madrenas J, Perez-Simon JA, Rodriquez R, Menendez P. Mesenchymal stem cells and their use as cell replacement therapy and disease modeling tool. J Cell Mol Med. 2008;12:2552–65.
- Moroff G, Seetharaman S, Kurtz JW, Greco NJ, Mullen MD, Lane TA, Law P. Retention of cellular properties of PBPCs following liquid storage and cryopreservation. Transfusion. 2004;44:245–52.
- Hubel A, Cariquist D, Clay M, McCullough J. Liquid storage, shipment, and cryopreservation of cord blood. Transfusion. 2004;44:518–25.
- Janssen WE, Lee CE. Shipping of bone marrow. Areman EM, Deeg HJ, Sacher RA. Bone Marrow and Stem Cell Processing: A Manual of Current Techniques. Philadelphia: FA Davis Company; 1992. 445–8.
- Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, Klingemann H. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy. 2008;10:625–32.
- Whiteside TL. Generation and characterization of human dendritic cells for therapy. Areman EM, Loper K. Cellular Therapy: Principles, Methods, and Regulations. Bethesda: AABB; 2009. 467–72.
- Savoldo B, Goss JA, Hammer MM, Zhang L, Lopez T, Gee AP, . Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood. 2006;108:2942–9.
- Sekiya I, Larson BL, Smith JR, Pochampally R, Cui J-G, Prockop DJ. Expansion of human adult stem cells from bone marrow stroma: conditions that maximize the yields of early progenitors and evaluate their quality. Stem Cells. 2002;6: 530–41.
- Whiteside TL, Bryant J, Day R, Herberman RB. Natural killer cytotoxicity in the diagnosis of immune dysfunction: criteria for a reproducible assay. J Clin Lab Anal. 1990;4: 102–14.
- Butterfield LH, Gooding W, Whiteside TL. Development of a potency assay for human dendritic cells: IL-12p70 production. J Immunother. 2008;31:89–100.
- Kenward MG, Roger JH. Small sample inference for fixed effects from restricted maximum likelihood. Biometrics. 1997;53:983–97.
- Searle S, Speed T, Milliken G. Population marginal means in the linear model; an alternative to least squares means. Am Stat. 1980;34:216–21.
- Edwards D, Berry J. The efficiency of simulation-based multiple comparisons. Biometrics. 1987;43:913–28.
- Singh P, Williams DJ. Cell therapies: realizing the potential of this new dimension to medical therapeutics. J Tissue Eng Regen Med. 2008;2:307–19.
- Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, . Long term outcome of EBV specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115:925–935.